{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-007007","form_type":"8-K","ticker":"CBDW","cik":"0001877461","company_name":"1606 CORP.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.217355+00:00","generated_at":"2026-05-30T02:16:55.223192+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"1606 Corp. target Adnexus merges with Sanctum for HIV and COVID-19 assets","bullets":["Adnexus Biotechnologies completed acquisition of Sanctum Therapeutics' core tech assets for HIV and SARS-CoV-2.","Combines Adnexus AI drug discovery platform with Sanctum's long-acting HIV capsid inhibitor and monoclonal antibodies.","1606 Corp. has a letter of intent for a 5% equity stake in Adnexus; LOI expires November 27, 2024.","CEO Austen Lambrecht calls merger a pivotal moment in fighting infectious diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-007007","json":"https://secwatch.observer/filing/0001477932-24-007007.json","markdown":"https://secwatch.observer/filing/0001477932-24-007007.md","text":"https://secwatch.observer/filing/0001477932-24-007007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877461/000147793224007007/0001477932-24-007007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877461/000147793224007007/cbdw_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:16:55.223192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}